It was 2024, and Dr. Evelyn Reed, a veteran of the U.S. Navy’s medical corps, had a problem. Her radiopharmaceutical startup, Novus Diagnostics, had a fantastic new tracer for detecting neurodegenerative diseases early, but actually making the stuff at scale was a total nightmare. The specialized manufacturing, the impossible-seeming regulations from the Food and Drug Administration (FDA), and the hunt for a skilled workforce made every single day feel like a slog. How was a small team like Novus Diagnostics, with its huge ambitions, supposed to break through these barriers and get its product to the patients who were waiting for it?
Key Takeaways
- Vets bring a specific kind of disciplined problem-solving that’s a perfect fit for the chaos of radiopharma manufacturing, where following a plan is everything.
- You can’t just walk into radiopharma. You need people who understand the guts of cyclotron operation, radiation safety, and strict Good Manufacturing Practices (GMP).
- To move faster, startups have to partner up with universities or established pharma companies, which can help get a new tracer to market years sooner by providing resources and distribution.
- Getting a new radiopharmaceutical through the FDA isn’t just paperwork. It means planning every single manufacturing step around their approval process from day one.
- Scaling up production means spending serious money on automation and quality control systems, it’s often the only way to make these drugs safely and effectively in large quantities.
Dr. Reed’s background was in nuclear medicine, a world where you live and die by precision and protocol. She knew the science cold. What she didn’t fully appreciate was just how hard it is to turn a lab success into a real-world product. Those first days at Novus Diagnostics, working out of a small facility near Emory University Hospital in Atlanta, Georgia, were a blur of long hours and chasing perfection. Her team, a mix of chemists, physicists, and engineers, many with their own military service records, shared that same drive.
The core challenge for Novus was really two problems: making their product the exact same way every time and getting the FDA to sign off on it. Their main compound, which was fluorine-18 based, needed a cyclotron to produce, and that equipment is both incredibly expensive to run and needs expert operators. “We could make small batches for clinical trials,” Dr. Reed said during one particularly tough week, “but scaling up to meet market demand, even a fraction of it, felt like trying to build a battleship in a bathtub.” The chaos of it all was where their veteran leadership started to pay off.
Reed’s first smart move was bringing in Marcus Thorne, a retired Army logistics officer whose whole career was managing supply chains for complex, high-stakes missions. Thorne’s arrival changed everything. He saw right away that Novus needed to stop thinking about individual problems and start looking at the entire system, almost like he was planning a military deployment. “In the Army, every person, every piece of gear, every backup plan has to sync up,” Thorne noted. “Radiopharma is a lot like that, with its short half-lives, critical timing, and zero room for error.” He quickly found bottlenecks in how they were buying precursor chemicals, saw that the cyclotron schedule was a mess, and pointed out that their quality assurance was all over the place.
Thorne got to work, applying the same lean manufacturing principles he’d used in military logistics. He started by simplifying how they procured isotopes and reagents, locking in long-term contracts with suppliers to make sure the materials actually showed up on time. He then built a sophisticated scheduling system for the cyclotron that squeezed every last drop of production out of it while still accounting for essential maintenance and calibration. This wasn’t just about moving faster. It was about creating a reliable process for a product that literally disappears if you wait too long.
Veteran homeowners. Want to lower your monthly payments?
See if a VA Cash Out Loan or VA Home Loan can put cash in your pocket or help you buy with $0 down. A specialist will review your options, free.
- VA Cash Out Loan: use up to 100% of your home’s equity
- VA Home Loan: buy a home with $0 down payment
- No cost, no obligation eligibility check
You’re all set.
A VA loan specialist will reach out shortly to review your Home Loan and Cash Out options.
The regulatory side of things was still a huge mountain to climb. The FDA’s rulebook for new drug applications (NDAs) is a beast, especially for new radiopharmaceuticals that might qualify for accelerated review because they address a serious medical need. Novus Diagnostics had to prove their tracer was safe and effective in trials, but they also had to show their manufacturing controls were rock-solid. You have to follow Good Manufacturing Practices (GMP), which are strict guidelines ensuring products are made to a consistent quality standard. In the radiopharma world, GMP isn’t just a suggestion. It dictates everything from how you build your facility to how you train your staff and document every single action.
So, Reed called a former colleague, Dr. Anya Sharma, a Navy physician who had become an expert in regulatory affairs for pharma companies. Dr. Sharma, who knew how to work inside massive bureaucracies, helped the Novus team make sense of the tangled FDA submission process. “The military teaches you to read a complex directive, understand what’s required, and get it done under pressure,” Dr. Sharma said. “That discipline is exactly what you need when you’re putting together an NDA package that might be hundreds of thousands of pages long.” Working together, they documented every part of Novus’s production process, from checking raw materials to releasing the final product, creating a bulletproof audit trail that would satisfy FDA 21 CFR Part 211. This intense focus on detail, something a lot of startups skip, saved them from endless back-and-forth with the agency later.
A perfect example came up with the facility’s ventilation system. It needed to meet incredibly high air purity standards to keep the sterile radiopharmaceutical product from getting contaminated. An early check showed the system was fine for research but would be an immediate fail for a commercial FDA inspection. Thorne didn’t panic. He got on the phone, used his network to find an engineering firm that specialized in cleanrooms, and managed a rapid redesign and install of a new HVAC system. His knack for identifying the real problem, finding the right people to fix it, and managing the project without derailing their ongoing research was exactly what they needed.
Having so many veterans on the team brought another benefit they hadn’t really expected: a shared culture of accountability. When a bad batch of a critical precursor chemical showed up with an unexpected impurity, nobody wasted time on blame. The team just quarantined the material, got on the phone with the supplier to figure out what went wrong, and immediately rejiggered the production schedule to use a backup source. No drama. That kind of operational discipline, which is drilled into you in the military, created a place where problems were just puzzles to be solved.
By late 2025, the difference Thorne’s logistical work had made was obvious. Their manufacturing process was finally efficient and, more importantly, consistent. The regulatory package was almost ready to go, thanks to Dr. Sharma’s guidance. They even managed to land a strategic partnership with a big pharmaceutical company, which gave them more funding and a path to a real distribution network. That deal only happened because Novus could prove they could scale and meet regulations, two things their veteran leadership had directly delivered. The bigger company was impressed by their methodical, no-excuses approach.
They weren’t at the finish line yet, clinical trials for the tracer were still running and final FDA approval was still on the horizon, but they’d solved the big initial problems of scaling up and getting their regulatory house in order. Dr. Reed often thought about how her military experience, and that of her team, gave them a kind of advantage. The ability to plan for every contingency, adapt when things go wrong, and execute a mission with discipline was the foundation of their success. It’s why these veteran contributions are so powerful in any industry that runs on precision and resilience.
Novus’s story really shows how the radiopharmaceutical industry, with its intense demands for precision, safety, and speed, benefits from the kind of problem-solving and operational focus that’s second nature to veteran leadership. The ability to turn a high-level goal into a detailed plan, manage a supply chain where timing is everything, and meet some of the toughest regulatory standards on the planet is a huge asset for any company trying to do hard things in healthcare.
What specific skills do veterans bring to the radiopharmaceutical industry?
They bring an obsession with process and safety. Think of things like managing complex supply chains under pressure or leading a team where one mistake with a radioactive material could be catastrophic, that’s daily life in both the military and in radiopharma. It’s about disciplined project management and a commitment to quality that’s been tested under fire.
How does military experience aid in working through FDA regulations for radiopharmaceuticals?
It’s about mindset. The military drills into you how to follow incredibly complex rules without deviation and document every single step. That’s exactly what the FDA demands when you’re preparing a New Drug Application (NDA) or proving you meet Good Manufacturing Practices (GMP). It’s less about knowing the rules beforehand and more about having the discipline to follow them perfectly.
What are the main challenges in scaling radiopharmaceutical production?
It boils down to time and purity. You’re working with isotopes that decay in hours, so your cyclotron schedule and supply chain have to be flawless. At the same time, every batch has to be perfectly sterile and consistent to meet quality standards and be safe for patients. You have to be fast and perfect, simultaneously.
Why is operational discipline particularly important in the radiopharma sector?
Because the stakes are so high. A product with a short half-life that’s delayed by a few hours becomes worthless garbage. A tiny process deviation can mean an ineffective or unsafe dose for a patient. There’s just no room for “good enough” when you’re dealing with radioactivity and medicine.
Can veterans with non-medical military backgrounds contribute to radiopharma?
Absolutely. A logistics officer like Marcus Thorne, for example, is perfect for untangling the supply chain for precursor chemicals and optimizing production schedules. An engineer could be the one to solve a critical facility problem, like an HVAC system that won’t pass an FDA inspection. The job title is less important than the proven ability to manage complex operations and solve hard problems.
